Rallybio CORP Schedule 13G passive stakes

Cormorant Asset Management, LP and Bihua Chen have reported a 0.0% beneficial ownership of Rallybio Corp. common stock, indicating a complete divestment.

Balyasny Asset Management L.P. and affiliated entities have filed a Schedule 13G amendment, reporting zero shares beneficially owned in Rallybio Corp.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 15.0% of Rallybio Corp's common stock as of June 30, 2026.

ADAR1 Capital Management and Daniel Schneeberger have reported a 17.5% beneficial ownership stake in Rallybio Corporation.

Viking Global Investors LP filed an amendment to its Schedule 13G, reporting a 9.99% beneficial ownership stake in Rallybio Corporation.

Nantahala Capital Management, LLC and its principals have reported a 5.68% beneficial ownership stake in Rallybio Corporation.

Cormorant Asset Management, LP and Bihua Chen have reported beneficial ownership of 400,000 shares, representing 7.56% of Rallybio Corp's common stock.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 7.12% of Rallybio Corp's common stock as of March 31, 2026.

Laurion Capital Management LP, along with individuals Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, has reported beneficial ownership of 5.72% of Rallybio Corp's common stock as of March 31, 2026.

Johnson & Johnson and its subsidiary JJDC have amended their Schedule 13G filing, reporting a combined beneficial ownership of 2.9% in Rallybio Corporation as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported a 10.6% beneficial ownership stake in Rallybio Corp's common stock.

FMR LLC, the parent company of Fidelity Investments, has reported a 7.1% beneficial ownership stake in Rallybio Corp common stock.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.3% of Rallybio Corp's common stock as of December 31, 2024.